Epidemiology of Pancreatic Cancer in Saudi Arabia: A Retrospective Analysis of Pancreatic Cancer Diagnosed in Saudi Arabia Between 2004 and 2015.
Middle-East
Saudi Arabia
epidemiology
incidence
pancreatic cancer
Journal
Clinical and experimental gastroenterology
ISSN: 1178-7023
Titre abrégé: Clin Exp Gastroenterol
Pays: New Zealand
ID NLM: 101532800
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
10
2020
accepted:
05
01
2021
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
20
2
2021
Statut:
epublish
Résumé
Over the last decades, the incidence of pancreatic cancer has increased, particularly in countries with a higher socioeconomic status. The present work aimed to provide detailed epidemiological data on the incidence of pancreatic cancer in Saudi Arabia. In this retrospective descriptive study, the epidemiological data on pancreatic cancer cases diagnosed in 13 administrative regions of Saudi Arabia between January 2004 and December 2015 were extracted from the Saudi Cancer Registry. The frequency, the crude incidence rate (CIR), and the age-standardized incidence rate (ASIR), stratified by geographical region, gender, and the year of diagnosis, were analyzed. From January 2004 to December 2015, a total of 2338 cases of pancreatic cancer were registered, including 1443 males and 895 females. The overall CIR was 1.28/100,000 among males and 0.80/100,000 in females, with an overall ASIR of 2.26 and 1.41/100,000 for males and females, respectively. Higher ASIR and CIR were observed among males than females (ratio 1.6). In both genders, the ASIR of pancreatic cancer increased with increasing age, with the highest incidence in patients aged 70 years or more. The ASIR in the Eastern Region (3.2/100,000) and the regions of Riyadh (3.0/100,000) and Tabuk (2.6/100,000) proved to be significantly higher than in the other regions of the country. Among women, the ASIR was significantly higher in Riyadh (2.3/100,000), the northern region (2.2/100,000), and Tabuk (2.0/100,000). This study revealed a slight increase of the CIR and ASIR of pancreatic cancer among males and females of the Saudi population. Eastern region, Riyadh, and Tabuk had the highest overall ASIRs of pancreatic cancer among males, Riyadh, Northern region, and Tabuk among Saudi females. The area least affected by pancreatic cancer was observed in Jazan among male and female Saudis. The rates of pancreatic cancer in Saudi Arabia were significantly higher among males compared with female Saudis. Further analytical studies are needed to identify the potential risk factors for pancreatic cancer among the Saudi population.
Identifiants
pubmed: 33603433
doi: 10.2147/CEG.S289269
pii: 289269
pmc: PMC7882803
doi:
Types de publication
Journal Article
Langues
eng
Pagination
45-57Informations de copyright
© 2021 Alghamdi et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Langenbecks Arch Surg. 2008 Jul;393(4):535-45
pubmed: 18193270
Pancreatology. 2019 Oct;19(7):941-950
pubmed: 31447281
Sci Rep. 2017 Jun 9;7(1):3165
pubmed: 28600530
Int J Cancer. 2010 May 15;126(10):2394-403
pubmed: 19790196
Br J Cancer. 2007 Feb 12;96(3):507-9
pubmed: 17224924
Rev Environ Health. 2015;30(3):191-205
pubmed: 26351801
Diabetes Res Clin Pract. 2010 Jan;87(1):4-14
pubmed: 19896746
Recent Results Cancer Res. 2016;208:95-105
pubmed: 27909904
Perspect Clin Res. 2019 Jan-Mar;10(1):34-36
pubmed: 30834206
J Epidemiol Glob Health. 2017 Dec;7(4):211-218
pubmed: 29110860
Onco Targets Ther. 2019 May 06;12:3387-3400
pubmed: 31118690
Arch Intern Med. 2010 May 10;170(9):791-802
pubmed: 20458087
BMC Cancer. 2018 Jun 25;18(1):688
pubmed: 29940910
Cancer Lett. 2016 Oct 10;381(1):269-77
pubmed: 27461582
BMC Public Health. 2015 Jul 05;15:611
pubmed: 26141062
Saudi Med J. 2004 Nov;25(11):1603-10
pubmed: 15573186
Br J Cancer. 2005 Jun 6;92(11):2076-83
pubmed: 15886696
Cancer Manag Res. 2020 Feb 13;12:1101-1111
pubmed: 32104090
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947
pubmed: 31648972
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Clin Oncol. 2019 Jan;16(1):11-26
pubmed: 30341417
World J Gastroenterol. 2016 Nov 28;22(44):9694-9705
pubmed: 27956793